Gene Therapy For Albinism

Journal of Advances in Biology & Biotechnology

16(3): 1-12, 2017; Article no.JABB.38504
ISS: 2394-1081

Treat Oculocutaneous Albinism with Gene Therapy

Martin L. Nelwan[1*]

[1]*Department of Animal Science – Other, Nelwan Institution for Human Resource Development Jl. A. Yani No. 24, Palu, Indonesia.*

Author's contribution

Author MLN designed the study, performed the literature searches, wrote the first draft of the manuscript and involved in revising the manuscript critically for significant intellectual need. The author read and approved the final manuscript.

Article Information

DOI: 10.9734/JABB/2017/38504
Editor(s):
(1) Andrzej Kowalski, Department of Biochemistry and Genetics, Institute of Biology, Jan Kochanowski University, Kielce, Poland.
Reviewers:
(1) Adam Reich, University of Rzeszow, Poland.
(2) Asaad Ahmed Ghanem, Mansoura University, Egypt.
(3) Silvana Guerriero, University of Bari, Italy.
Complete Peer review History: http://www.sciencedomain.org/review-history/22563

Review Article

Received 29th November 2017
Accepted 22nd December 2017
Published 2nd January 2018

ABSTRACT

Oculocutaneous albinism (OCA) is a group of hereditary recessive disorder recognized as a loss of pigmentation. OCA can derive from mutations in different genes that produce melanin. These mutations cause disturbances to get a standard melanin synthesis. There are 7 types of oculocutaneous albinism. These include OCA1, OCA2, OCA3, OCA4, OCA5, OCA6, and OCA7. To help OCA patients, it may include management of such as hats with brims and sunscreens. An effective therapy is unavailable for albinism at present. However, to fight OCA in the future, gene therapy can be used. Gene therapy can include use of such as retrovirus vectors, adenovirus vectors, and CRISPR/Cas9 system. Research results in animal models have shown remarkable advances. It means that the gene therapy will be helpful to treat people with albinism.

Keywords: Albinism; albino; oculocutaneous albinism; gene therapy.

1. INTRODUCTION

Oculocutaneous albinism (OCA) is a heterogeneous group of monogenic recessive disorder. It is a reduction of pigmentation resulting in hypopigmentation in the eyes, hair and skin. Characteristic eye features include reduced visual acuity, nystagmus, strabismus, photophobia, foveal, and reduced iris [1,2,3]. Tomita and Miyamura reported that the

**Corresponding author: E-mail: mlnelwan2@gmail.com;*

Gene therapy for albinism represents a groundbreaking approach to addressing a genetic condition that affects the pigmentation of skin, hair, and eyes. Albinism is primarily caused by mutations in genes responsible for the production of melanin, the pigment that gives color to these features. The condition can lead to various health issues, including vision problems and an increased risk of skin cancer due to a lack of protective pigment. As research continues to advance, gene therapy emerges as a promising avenue for treating albinism, offering hope for individuals affected by this genetic disorder. This article delves into the underlying causes of albinism, the current state of gene therapy, its potential benefits, challenges, and future prospects.

Understanding Albinism

Types of Albinism

Albinism is categorized into several types, primarily based on the specific genetic mutations involved. The most common types include:

1. Oculocutaneous Albinism (OCA): This type affects the skin, hair, and eyes and is further divided into several subtypes (OCA1, OCA2, OCA3, OCA4) based on different genetic mutations.
2. Ocular Albinism (OA): This type primarily affects the eyes, leading to vision issues while typically leaving skin and hair pigmentation unaffected. The most common form is X-linked ocular albinism (XOA).
3. Hermansky-Pudlak Syndrome: This rare form of albinism is associated with bleeding disorders and other systemic issues.

Causes of Albinism

Albinism is caused by mutations in genes that are crucial for the production and distribution of melanin. The most significant genes implicated in albinism include:

- TYR: Mutations in this gene lead to OCA1, affecting melanin production in melanocytes.
- OCA2: This gene is associated with OCA2 and is critical for melanin synthesis.
- TYRP1: Mutations in this gene can lead to OCA3, affecting the type of melanin produced.
- SLC45A2: This gene is linked to OCA4 and is involved in melanin production.

The inheritance pattern for albinism can be autosomal recessive or X-linked, depending on the specific type.

Current Treatments for Albinism

Currently, there is no cure for albinism, and treatment focuses on managing symptoms and preventing complications. Common approaches include:

- Sunscreen and Protective Clothing: Individuals with albinism are at higher risk for skin cancer, making sun protection crucial.
- Vision Aids: Due to vision problems associated with albinism, corrective lenses and other aids can help improve sight.
- Educational Support: Specialized educational resources can assist individuals with learning difficulties related to vision issues.

While these treatments are effective in managing symptoms, they do not address the underlying genetic causes of albinism, highlighting the need for innovative approaches like gene therapy.

Gene Therapy: An Overview

Gene therapy involves introducing, removing, or altering genetic material within a patient's cells to treat or prevent disease. This approach has shown promise in various genetic disorders, and albinism is emerging as a potential target due to its clear genetic basis.

Mechanisms of Gene Therapy

Gene therapy can be conducted through several methods:

1. Gene Replacement: Introducing a healthy copy of the mutated gene into the patient's cells.
2. Gene Editing: Utilizing technologies like CRISPR-Cas9 to correct mutations directly at the genetic level.
3. Gene Silencing: Reducing the expression of harmful genes that may contribute to the disease.

In the case of albinism, gene replacement or editing could aim to restore the function of the mutated melanin-producing genes.

Research and Developments in Gene Therapy for Albinism

Recent advancements in gene therapy have sparked interest in developing treatments for albinism. Research efforts are primarily focused on:

- Preclinical Studies: These studies involve animal models to test the safety and efficacy of gene therapies targeting specific forms of albinism.
- Clinical Trials: Several trials have been initiated to evaluate the effectiveness of gene therapy in humans, particularly for OCA1 and OCA2.

Successful Case Studies

While clinical applications are still in their infancy, there have been some promising case studies:

- Ocular Albinism: Initial research has shown that gene therapy can improve

retinal function in animal models of ocular albinism, leading to enhanced vision.
- Oculocutaneous Albinism: Studies involving gene delivery systems have successfully restored pigmentation in affected animal models, demonstrating the potential for similar outcomes in humans.

Potential Benefits of Gene Therapy for Albinism

The introduction of gene therapy for albinism could offer several significant benefits:

- Addressing the Root Cause: Unlike current treatments, gene therapy could potentially correct the genetic defects that cause albinism.
- Improved Quality of Life: Successful gene therapy could lead to better pigmentation, reducing the risk of skin cancer and improving vision.
- Long-term Solutions: Gene therapy could provide a long-lasting solution that eliminates the need for ongoing symptomatic treatments.

Challenges and Ethical Considerations

While gene therapy holds immense promise, several challenges and ethical considerations must be addressed:

- Safety and Efficacy: Ensuring that gene therapy is safe and effective for long-term use is paramount. Ongoing research is necessary to monitor potential side effects.
- Accessibility: The high cost of gene therapy may limit access, raising concerns about equity in treatment availability.
- Ethical Implications: The prospect of genetic modification raises ethical questions about the extent to which we should alter human DNA and the potential for unintended consequences.

Future Prospects

The future of gene therapy for albinism is hopeful yet uncertain. Continued research and clinical trials are essential to confirm the safety and efficacy of these innovative treatments. As technology advances, we may see the development of more refined gene delivery methods and improved targeting techniques. Furthermore, public awareness and education about albinism and gene therapy can help reduce stigma and promote acceptance.

In conclusion, gene therapy for albinism represents an exciting frontier in genetic medicine. As scientists continue to unravel the complexities of this condition, the potential for transformative treatments becomes increasingly

tangible. With ongoing research, collaboration, and ethical considerations, gene therapy could pave the way for a brighter future for individuals affected by albinism.

Frequently Asked Questions

What is gene therapy for albinism?

Gene therapy for albinism involves altering the genes responsible for melanin production in order to treat or mitigate the effects of the condition, potentially restoring pigment to the skin, hair, and eyes.

How does gene therapy address the genetic mutations that cause albinism?

Gene therapy aims to correct or replace the faulty genes associated with albinism, such as the TYR, OCA2, and TYRP1 genes, using techniques like CRISPR or viral vectors to introduce functional copies of these genes into the patient's cells.

What are the potential benefits of gene therapy for individuals with albinism?

Potential benefits include improved pigmentation, enhanced visual function, reduced sensitivity to sunlight, and overall better quality of life by addressing the cosmetic and health challenges associated with albinism.

What are the risks associated with gene therapy for albinism?

Risks may include immune reactions, unintended genetic changes, and complications from the delivery method of the therapy, such as viral vector-associated issues.

Are there any clinical trials currently underway for gene therapy targeting albinism?

Yes, several clinical trials are investigating gene therapy approaches for albinism, focusing on safety, efficacy, and long-term outcomes for patients with varying types of the condition.

How is gene therapy for albinism different from traditional treatments?

Unlike traditional treatments that primarily manage symptoms (like sunscreen or corrective lenses), gene therapy aims to address the root cause of albinism by repairing or replacing the defective genes responsible for the

condition.

What advancements have been made in gene therapy for albinism in recent years?

Recent advancements include the successful use of CRISPR technology to edit genes in laboratory models, improved delivery methods for gene therapy, and promising early results from clinical studies.

What is the future outlook for gene therapy in treating albinism?

The future outlook is optimistic, with ongoing research likely to lead to approved therapies, increased public awareness, and potentially transformative outcomes for individuals living with albinism.

Find other PDF article:
https://soc.up.edu.ph/40-trend/files?docid=DKs84-2390&title=mcgraw-hill-organic-chemistry-solutions-manual-chandra.pdf

Gene Therapy For Albinism

Geneanet - Généalogie : recherchez vos ancêtres, publiez votre ...
Généalogie : créez gratuitement votre arbre généalogique et retrouvez vos ancêtres en ligne parmi plus de 9 milliards d'individus référencés !

□□□□□□□□Gene, allele, SNP□□□□□□□□□□□ - □□
□□□□□ □□□□ □□□□□□□□Gene, allele, SNP□□□□□□□□□□□ □□□□□□□□□ [□□] □□□□□□□□Gene, allele, SNP□□□□□ □□□□□□□□□□□□□ □ ...

Rechercher dans toutes les données - Geneanet
Recherchez vos ancêtres sur la première base de données généalogique européenne.

□□□□□□□□Gene, allele, SNP□□□□□□□□□□□
□□□□□□□□Gene, allele, SNP□□□□□□□□□□□ □□□ · undefined □□□□□□□□□ □□□□□□□□□ [□□] □□□□□□□□Gene, allele, SNP□□□□□□□□□□□ ...

□□□□□□□gene□chromosome□allele□RNA□DNA□□□□ ...
□□□□□□□□□□□□□RNA□□DNA□□□□□DNA□□□□□□□□□□RNA□□□DNA□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□gene□□□) ...

□□□□□□□ (Gene Set Enrichment Analysis, GSEA□
GSEA□Gene Set Enrichment Analysis□□□□□□□□2005□□Gene set enrichment analysis: a knowledge-based approach forinterpreting genome-wide expression profiles□□□□□□□ ...

□□□gene ID □□□□□□□gene name□ - □□
type_of_gene: □□□□□□□Protein coding□ Symbol_from_nomenclature_authority: □□□□□□□□□□□□□□□□ □BRCA1□ Full_name_from_nomenclature_authority: □□□□ …

Les décès en France depuis 1970 (INSEE) - Geneanet
L’INSEE diffuse depuis la fin 2019, en accès libre, les décès répertoriés en France. Une aide considérable pour les généalogistes.

□NCBI□□□□gene□□□□□□□□□□□□□□□□□□□□□ …
□□□□□□□NCBI□gene□□□□□□□□□□□□□□□□□□□□□□□□□□□□□

Faites votre généalogie gratuitement en ligne - Geneanet
Débutez facilement votre arbre généalogique sur Geneanet. Ajoutez votre famille puis partez à la recherche de vos ancêtres !

Geneanet - Généalogie : recherchez vos ancêtres, publiez votre ...
Généalogie : créez gratuitement votre arbre généalogique et retrouvez vos ancêtres en ligne parmi plus de 9 milliards d'individus …

□□□□□□□Gene, allele, SNP□□□□□□□□□□□□ - □□
□□□□□ □□□□ □□□□□□□Gene, allele, SNP□□□□□□□□□□□□ □□□□□□□□□ [□□] □□□□□□□Gene, allele, SNP□□□□ …

Rechercher dans toutes les données - Geneanet
Recherchez vos ancêtres sur la première base de données généalogique européenne.

□□□□□□□Gene, allele, SNP□□□□□□□□□□□□
□□□□□□□Gene, allele, SNP□□□□□□□□□□□□ □□□ · undefined □□□□□□□□□ □□□□□□□□□ [□□] □□□□□□□Gene, …

□□□□□□gene□chromosome□allele□RNA□...
□□□□□□□□□□□□RNA□□DNA□□□□□DNA□□□□□□□□□□RNA□□□DNA□□□□□□□□□□□□□□□□□□□□□□□□□□□□ …

Discover how gene therapy for albinism is transforming lives. Explore innovative treatments and advancements in this groundbreaking field. Learn more!

Back to Home